1 Min Read
Jan 4 (Reuters) - Foamix Pharmaceuticals Ltd:
* FOAMIX ANNOUNCES POSITIVE RESULTS FROM PHASE 3 OPEN-LABEL SAFETY EXTENSION EVALUATING FMX-101 TOPICAL MINOCYCLINE FOAM FOR TREATMENT UP TO 1 YEAR Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.